Loading...
01/11 03:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong MRD revenue growth, positive adjusted EBITDA, and raised guidance, alongside strategic initiatives like EMR integrations and collaborations. The Q&A session reinforces the positive outlook with sustained volume growth and international expansion opportunities. Despite some management ambiguity, the overall sentiment is optimistic, driven by strong financial performance and strategic partnerships.
MRD business adjusted EBITDA Achieved profitability this quarter with approximately $2 million in positive adjusted EBITDA, marking a significant milestone.
MRD revenue Grew 42% year-over-year, driven by significant increases in clinical volume and integration of clonoSEQ into Flatiron's OncoEMR.
Total company sequencing gross margin Improved by 14 percentage points year-over-year to 64%, attributed to scaling operations and improving margins.
Cash burn for the quarter Approximately $11 million, representing a 36% improvement over the same period last year, ending with a cash position of $222 million.
clonoSEQ revenue Grew 57% year-over-year in the second quarter, driven by strong demand across all reimbursed indications.
clonoSEQ test volumes Delivered over 25,300 tests, up 37% versus prior year and up 10% sequentially, reflecting increased demand.
Blood-based testing for MRD Represents 44% of MRD tests, up 40% from a year ago, with multiple myeloma blood-based contribution rising to 23% compared to 21% last quarter.
ASP for clonoSEQ Reached above $1,290 per test, a 17% increase year-over-year, driven by contracting initiatives and improved pricing.
MRD Pharma revenue Increased 20% year-over-year, inclusive of $5.5 million in milestones, with a $218 million backlog, up 21% from the prior year.
Total revenue $58.9 million, representing 36% growth from the same period last year, with 85% from MRD business and 15% from Immune Medicine.
Immune Medicine revenue $8.9 million, up 13% from a year ago, reflecting steady growth.
Net loss for the quarter $25.6 million, reflecting ongoing investments and operational costs.
clonoSEQ integration into Flatiron's OncoEMR: Expanded access in the community, enabling streamlined ordering and serial testing.
clonoSEQ tests on NovaSeq X: Improved scaling operations and margins.
Enhanced clonoSEQ ctDNA assay: FDA granted investigational device exemptions for trials in DLBCL.
MRD revenue growth: 42% year-over-year increase, driven by clinical volume.
Global clinical trials: 175 active trials with a $218 million backlog, up 21% year-over-year.
European Medicines Agency support: Positive opinion for MRD testing as an early endpoint in multiple myeloma.
Sequencing gross margin: Improved by 14 percentage points year-over-year to 64%.
Cash burn reduction: 36% improvement year-over-year, ending with $222 million in cash.
EMR integrations: Achieved integration into 40 Epic sites and 113 Flatiron community account groups.
MRD profitability: Achieved positive adjusted EBITDA of $2 million, ahead of schedule.
Immune Medicine goals: Progress in digital TCR-antigen prediction model and T cell depletion program.
Updated full-year guidance: Raised MRD revenue range to $190-$200 million and lowered cash burn guidance.
Regulatory Developments: The company is monitoring developments at the FDA and other regulatory bodies. While there is optimism about global support for MRD testing, any delays or unfavorable decisions could impact the adoption of MRD as a central element in drug development strategies.
Cash Burn and Financial Sustainability: Although the company has improved its cash burn guidance, Immune Medicine still anticipates a burn of $25 million to $30 million for the year. This could strain financial resources if revenue growth does not meet expectations.
Operational Scaling: The integration of clonoSEQ into EMR systems and scaling operations with NovaSeq X are critical for growth. Any delays or inefficiencies in these processes could hinder the company’s ability to meet demand and improve margins.
Market Competition: The company is expanding its footprint in community oncology and academic settings. However, competitive pressures in these markets could limit growth and adoption of their products.
Reimbursement Challenges: While ASP for clonoSEQ has increased, the company is still in the process of closing additional agreements with payers. Delays or failures in these negotiations could impact revenue.
Dependence on Milestone Payments: A significant portion of MRD Pharma revenue is tied to milestone payments, which are contingent on regulatory approvals and clinical trial outcomes. Any setbacks in these areas could affect financial performance.
Technological Development Risks: The company is developing a digital TCR-antigen prediction model and scaling AI/machine learning applications. Delays or failures in these technological advancements could impact future partnering opportunities and revenue generation.
MRD Revenue Guidance: The company has raised its full-year MRD revenue guidance to a range of $190 million to $200 million, up from the previous range of $180 million to $190 million. This increase is driven by stronger-than-expected clinical volume performance and higher anticipated MRD milestone revenue for the year.
clonoSEQ Test Volume Growth: The company expects approximately 35% growth in fiscal year 2025 clonoSEQ test volumes compared to 2024, with sequential growth anticipated in both the third and fourth quarters.
MRD Milestone Revenue: Revenue from MRD milestones is expected to be between $14 million and $15 million, up from the previous guidance of $8 million to $9 million.
Total Company Cash Burn Guidance: The company has lowered its full-year total company cash burn guidance to a range of $45 million to $55 million, down from the prior range of $50 million to $60 million. This improvement is primarily driven by higher-than-expected MRD revenue.
MRD Business Profitability: The MRD business achieved positive adjusted EBITDA of $1.9 million in Q2 2025 and is expected to maintain positive adjusted EBITDA going forward, with a clear pathway to cash breakeven in the near term.
Immune Medicine Cash Burn: The Immune Medicine segment is expected to have a cash burn of $25 million to $30 million for fiscal year 2025.
Sequencing Gross Margin: Sequencing gross margin improved to 64% in Q2 2025, representing a 14 percentage point increase year-over-year, and is expected to continue benefiting from higher volumes and pricing.
Regulatory and Market Trends: The European Medicines Agency issued a positive opinion supporting the use of MRD testing as an early endpoint for conditional approval in multiple myeloma, aligning with the ODAC recommendation. This is expected to drive further adoption of MRD testing globally.
The selected topic was not discussed during the call.
The earnings call summary and Q&A section reveal several positive aspects: raised revenue guidance, improved margins, and strong growth in MRD volumes. The company's strategic partnerships and regulatory advancements, along with a clear path to profitability, are positive indicators. Despite some vague management responses, the overall sentiment is optimistic. The stock is likely to see a positive movement, with increased MRD revenue and improved cash burn guidance contributing to investor confidence.
The earnings call highlights strong MRD revenue growth, positive adjusted EBITDA, and raised guidance, alongside strategic initiatives like EMR integrations and collaborations. The Q&A session reinforces the positive outlook with sustained volume growth and international expansion opportunities. Despite some management ambiguity, the overall sentiment is optimistic, driven by strong financial performance and strategic partnerships.
The earnings call highlights significant revenue growth, improved margins, and reduced losses, which are positive indicators. The Q&A reveals strong growth in specific indications and EMR integrations, although some management responses lack clarity. The lowered spending guidance is a positive sign of cost control. Despite a net loss, the improved cash position and strategic partnerships like NeoGenomics suggest optimism. The overall sentiment is positive, with potential stock price appreciation in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
